# Phanes Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/phanes-therapeutics

- Industry: Pharmaceuticals
- Headquarters: San Diego, US
- Website: www.phanesthera.com
- Total disclosed funding: $40M
- Latest round: Series B (May 6, 2021)
- Investors on record: 5

## About

Established in 2016 and based in San Diego, US, Phanes Therapeutics, Inc. is biotech company that engages in research and developing innovative drugs in immuno-oncology and eye disease. The company founder and CEO, Dr.Wang Minghan, was a former vice president of Johnson & Johnson.

The company mainly operates two technology platforms, PACbody and ATACCbody. The PACbody platform can constructs native IgG-like bispecific antibodies. The ATACCbody platform can build bispecific antibodies with modulated activities. It aim to use immuno-oncology molecules to treat tumor diseases.

## Funding rounds

- Series B, May 6, 2021, $40M — Hong Shan, K2VC, Delos Capital Partners, DYEE Capital, Volcanics Venture
- Series A, Nov 1, 2018 — K2VC

## Investors

- K2VC (https://capitalatlas.ai/funds/k2vc) — Series A, Series B
- Hong Shan — Series B
- Delos Capital Partners (https://capitalatlas.ai/funds/delos-capital-partners) — Series B
- DYEE Capital (https://capitalatlas.ai/funds/dyee-capital) — Series B
- Volcanics Venture (https://capitalatlas.ai/funds/volcanics-venture) — Series B